|
1
|
de Dombal FT, Burch PR and Watkinson G:
Aetiology of ulcerative colitis. Gut. 10:270–277. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cho JH and Brant SR: Recent insights into
the genetics of inflammatory bowel disease. Gastroenterology.
140:1704–1712. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thompson AI and Lees CW: Genetics of
ulcerative colitis. Inflamm Bowel Dis. 17:831–848. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Danese S and Fiocchi C: Ulcerative
colitis. N Engl J Med. 365:1713–1725. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eaden JA, Abrams KR and Mayberry JF: The
risk of colorectal cancer in ulcerative colitis: A meta-analysis.
Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Munkholm P: Review article: The incidence
and prevalence of colorectal cancer in inflammatory bowel disease.
Aliment Pharmacol Ther. 18 Suppl 2:S1–S5. 2003. View Article : Google Scholar
|
|
7
|
Jess T, Rungoe C and Peyrin-Biroulet L:
Risk of colorectal cancer in patients with ulcerative colitis: A
meta-analysis of population-based cohort studies. Clin
Gastroenterol Hepatol. 10:639–645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choi PM, Nugent FW, Schoetz DJ Jr,
Silverman ML and Haggitt RC: Colonoscopic surveillance reduces
mortality from colorectal cancer in ulcerative colitis.
Gastroenterology. 105:418–424. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vleggaar FP, Lutgens MW and Claessen MM:
Review article: The relevance of surveillance endoscopy in
long-lasting inflammatory bowel disease. Aliment Pharmacol Ther. 26
Suppl 2:S47–S52. 2007. View Article : Google Scholar
|
|
10
|
Jess T, Frisch M and Simonsen J: Trends in
overall and cause-specific mortality among patients with
inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol
Hepatol. 11:43–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Herrinton LJ, Liu L, Levin TR, Allison JE,
Lewis JD and Velayos F: Incidence and mortality of colorectal
adenocarcinoma in persons with inflammatory bowel disease from 1998
to 2010. Gastroenterology. 143:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Poulsom R and Wright NA: Trefoil peptides:
A newly recognized family of epithelial mucin-associated molecules.
Am J Physiol. 265:G205–G213. 1993.PubMed/NCBI
|
|
13
|
Thim L: Trefoil peptides: A new family of
gastrointestinal molecules. Digestion. 55:353–360. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wright NA, Poulsom R, Stamp G, Van Noorden
S, Sarraf C, Elia G, Ahnen D, Jeffery R, Longcroft J, Pike C, et
al: Trefoil peptide gene expression in gastrointestinal epithelial
cells in inflammatory bowel disease. Gastroenterology. 104:12–20.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Madsen J, Nielsen O, Tornøe I, Thim L and
Holmskov U: Tissue localization of human trefoil factors 1, 2, and
3. J Histochem Cytochem. 55:505–513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao
CM, Podolsky DK and Wang TC: TFF2/SP-deficient mice show decreased
gastric proliferation, increased acid secretion, and increased
susceptibility to NSAID injury. J Clin Invest. 109:193–204. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Babyatsky MW, deBeaumont M, Thim L and
Podolsky DK: Oral trefoil peptides protect against ethanol- and
indomethacin-induced gastric injury in rats. Gastroenterology.
110:489–497. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taupin D and Podolsky DK: Trefoil factors:
Initiators of mucosal healing. Nat Rev Mol Cell Biol. 4:721–732.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kinoshita K, Taupin DR, Itoh H and
Podolsky DK: Distinct pathways of cell migration and antiapoptotic
response to epithelial injury: Structure-function analysis of human
intestinal trefoil factor. Mol Cell Biol. 20:4680–4690. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dignass A, Lynch-Devaney K, Kindon H, Thim
L and Podolsky DK: Trefoil peptides promote epithelial migration
through a transforming growth factor beta-independent pathway. J
Clin Invest. 94:376–383. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kirikoshi H and Katoh M: Expression of
TFF1, TFF2 and TFF3 in gastric cancer. Int J Oncol. 21:655–659.
2002.PubMed/NCBI
|
|
22
|
Leung WK, Yu J, Chan FK, To KF, Chan MW,
Ebert MP, Ng EK, Chung SC, Malfertheiner P and Sung JJ: Expression
of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas,
intestinal metaplasia, and non-neoplastic gastric tissues. J
Pathol. 197:582–588. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamachika T, Werther JL, Bodian C,
Babyatsky M, Tatematsu M, Yamamura Y, Chen A and Itzkowitz S:
Intestinal trefoil factor: A marker of poor prognosis in gastric
carcinoma. Clin Cancer Res. 8:1092–1099. 2002.PubMed/NCBI
|
|
24
|
Dhar DK, Wang TC, Tabara H, Tonomoto Y,
Maruyama R, Tachibana M, Kubota H and Nagasue N: Expression of
trefoil factor family members correlates with patient prognosis and
neoangiogenesis. Clin Cancer Res. 11:6472–6478. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morito K, Nakamura J, Kitajima Y, Kai K,
Tanaka T, Kubo H, Miyake S and Noshiro H: The value of trefoil
factor 3 expression in predicting the lon-gterm outcome and early
recurrence of colorectal cancer. Int J Oncol. 46:563–568. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang YG, Li YF, Wang LP and Zhang Y:
Aberrant expression of trefoil factor 3 is associated with
colorectal carcinoma metastasis. J Cancer Res Ther. 9:376–380.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Southgate HW: Note on preparing
mucicarmine. J Pathol Bacteriol. 30:7291927. View Article : Google Scholar
|
|
28
|
Sobin LH and Wittekind Ch: UICC TNM
Classification of Malignant Tumors. 6th edition. John Wiley and
Sons; New York: pp. 52–56. 2002
|
|
29
|
Xiao L, Liu YP, Xiao CX, Ren JL and Guleng
B: Serum TFF3 may be a pharamcodynamic marker of responses to
chemotherapy in gastrointestinal cancers. BMC Clin Pathol.
14:262014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
John R, El-Rouby NM, Tomasetto C, Rio MC
and Karam SM: Expression of TFF3 during multistep colon
carcinogenesis. Histol Histopathol. 22:743–751. 2007.PubMed/NCBI
|
|
31
|
Gu J, Zheng L, Zhang L, Chen S, Zhu M, Li
X and Wang Y: TFF3 and HER2 expression and their correlation with
survival in gastric cancer. Tumour Biol. 36:3001–3007. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pandey V, Wu ZS, Zhang M, Li R, Zhang J,
Zhu T and Lobie PE: Trefoil factor 3 promotes metastatic seeding
and predicts poor survival outcome of patients with mammary
carcinoma. Breast Cancer Res. 16:4292014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Garraway IP, Seligson D, Said J, Horvath S
and Reiter RE: Trefoil factor 3 is overexpressed in human prostate
cancer. Prostate. 61:209–214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Neutra M and Leblond CP: Synthesis of the
carbohydrate of mucus in the golgi complex as shown by electron
microscope radioautography of goblet cells from rats injected with
glucose-H3. J Cell Biol. 30:119–136. 1996. View Article : Google Scholar
|
|
35
|
Suemori S, Lynch-Devaney K and Podolsky
DK: Identification and characterization of rat intestinal trefoil
factor: Tissue- and cell-specific member of the trefoil protein
family. Proc Natl Acad Sci USA. 88:11017–11021. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taupin D, Ooi K, Yeomans N and Giraud A:
Conserved expression of intestinal trefoil factor in the human
colonic adenoma-carcinoma sequence. Lab Invest. 75:25–32.
1996.PubMed/NCBI
|
|
37
|
Sands BE and Podolsky DK: The trefoil
peptide family. Annu Rev Physiol. 58:253–273. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mashimo H, Wu DC, Podolsky DK and Fishman
MC: Impaired defense of intestinal mucosa in mice lacking
intestinal trefoil factor. Science. 274:262–265. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ullman T, Odze R and Farraye FA: Diagnosis
and management of dysplasia in patients with ulcerative colitis and
Crohn's disease of the colon. Inflamm Bowel Dis. 15:630–638. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Itzkowitz SH and Present DH: Crohn's and
Colitis Foundation of America Colon Cancer in IBD Study Group:
Consensus conference: Colorectal cancer screening and surveillance
in inflammatory bowel disease. Inflamm Bowel Dis. 11:314–321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rutter MD, Saunders BP, Wilkinson KH,
Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC
and Forbes A: Thirty-year analysis of a colonoscopic surveillance
program for neoplasia in ulcerative colitis. Gastroenterology.
130:1030–1038. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kornbluth A and Sachar DB: Practice
Parameters Committee of the American College of Gastroenterology:
Ulcerative colitis practice guidelines in adults: American college
of gastroenterology, practice parameters committee. Am J
Gastroenterol. 105:501–523. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Collins PD, Mpofu C, Watson AJ and Rhodes
JM: Strategies for detecting colon cancer and/or dysplasia in
patients with inflammatory bowel disease. Cochrane Database Syst
Rev. 19:CD0002792006.
|
|
44
|
Hata K, Watanabe T, Kazama S, Suzuki K,
Shinozaki M, Yokoyama T, Matsuda K, Muto T and Nagawa H: Earlier
surveillance colonoscopy programme improves survival in patients
with ulcerative colitis associated colorectal cancer: Results of a
23-year surveillance programme in the Japanese population. Br J
Cancer. 89:1232–1236. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rex DK: Preventing colorectal cancer and
cancer mortality with colonoscopy: What we know and what we don't
know. Endoscopy. 42:320–323. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen R, Rabinovitch PS, Crispin DA, Emond
MJ, Koprowicz KM, Bronner MP and Brentnall TA: DNA fingerprinting
abnormalities can distinguish ulcerative colitis patients with
dysplasia and cancer from those who are dysplasia/cancer-free. Am J
Physiol. 162:665–672. 2003.
|
|
47
|
Neumann H, Vieth M, Langner C, Neurath MF
and Mudter J: Cancer risk in IBD: How to diagnose and how to manage
DALM and ALM. World J Gastroenterol. 17:3184–3191. 2011.PubMed/NCBI
|
|
48
|
Chai H and Brown RE: Field effect in
cancer-an update. Ann Clin Lab Sci. 39:331–337. 2009.PubMed/NCBI
|
|
49
|
Slaughter DP, Southwick HW and Smejkal W:
Field cancerization in oral stratified squamous epithelium;
clinical implications of multicentric origin. Cancer. 6:963–968.
1953. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Watanabe T, Kobunai T, Yamamoto Y, Ikeuchi
H, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T,
et al: Predicting ulcerative colitis-associated colorectal cancer
using reverse-transcription polymerase chain reaction analysis.
Clin Colorectal Cancer. 10:134–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hsieh CJ, Klump B, Holzmann K, Borchard F,
Gregor M and Porschen R: Hypermethylation of the p16INK4a promoter
in colectomy specimens of patients with long-standing and extensive
ulcerative colitis. Cancer Res. 58:3942–3945. 1998.PubMed/NCBI
|
|
52
|
Risques RA, Lai LA, Himmetoglu C, Ebaee A,
Li L, Feng Z, Bronner MP, Al-Lahham B, Kowdley KV, Lindor KD, et
al: Ulcerative colitis-associated colorectal cancer arises in a
field of short telomeres, senescence, and inflammation. Cancer Res.
71:1669–1679. 2011. View Article : Google Scholar : PubMed/NCBI
|
